Cancer Research AACR Legacy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huerta, S.
Right arrow Articles by Koeffler, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huerta, S.
Right arrow Articles by Koeffler, H. P.
[Cancer Research 62, 5204-5209, September 15, 2002]
© 2002 American Association for Cancer Research


Carcinogenesis

PC-SPES Inhibits Colon Cancer Growth in Vitro and in Vivo1

Sergio Huerta2, James R. Arteaga, Ronald W. Irwin, Takayuki Ikezoe, David Heber and H. Phillip Koeffler

University of California Los Angeles (UCLA) Center for Human Nutrition [S. H., J. R. A., R. W. I., D. H.], Division of Hematology/Oncology Cedar Sinai Research Institute [T. I., H. P. K.], UCLA School of Medicine, Los Angeles, California 90095

PC-SPES is a mixture of eight herbs with antiproliferative activity in prostate cancer cell lines and antitumor effects in animal models of prostate cancer. In addition, evidence of clinical efficacy in advanced prostate cancer has been reported. PC-SPES has also been shown to have antitumor activity against several other cancer cell lines including breast and neuroepithelial cancer, melanoma, and leukemia cell lines. Because of these findings, we investigated the effects of PC-SPES in vitro in colon cancer cell lines SW480, SW620, and DLD-1 and in vivo in the Apcmin mouse, a murine model for intestinal carcinogenesis. For the in vitro studies, colon cancer cell lines were exposed to an ethanolic extract of PC-SPES compared with a diluent control [ethanol <= 0.3% (v/v)]. PC-SPES resulted in a marked suppression of cell proliferation in all colon cancer cells studied. PC-SPES (3 µl/ml) caused a 95% inhibition of cell proliferation of the DLD-1 colon cancer cell line, and similar results were observed in the SW480 and SW620 colon cancer cell lines. Cell cycle analysis demonstrated a drastic (>=60%) accumulation of cells in the G2-M phase with a concomitant decrease of cells in the G0-G1 phase in all colon cancer cell lines studied after treatment with PC-SPES (1.5 µl/ml for 48 h). Western blot analysis demonstrated a decrease in protein levels of ß-tubulin in the SW620 cell line exposed to PC-SPES. Terminal deoxynucleotidyl transferase-mediated nick end labeling analysis revealed an increase in apoptotic colon cancer cells incubated with PC-SPES. For the in vivo studies, female 4–5-week-old Apcmin mice were randomized to two groups: a PC-SPES-treated group (n = 11) received 250 mg/kg/day (0.2 ml) PC-SPES via gastrointestinal gavage; and a control group (n = 10) received 0.2 ml of the vehicle solution (1.5% carboxymethylcellulose with 0.2% Tween 20) via gastrointestinal gavage. Both groups were treated five times a week for 10 weeks. After treatment, the gastrointestinal tract was dissected for polyp scoring by two observers blinded to treatment. The Apcmin mice given PC-SPES had a 58% reduction in tumor number and a 56% decrease in tumor load. No effect on either food intake or body weight was observed in the treated versus sham groups. The present study is the first to report the potent activity of PC-SPES against colon cancer. Both cell cycle arrest and apoptosis occurred after treatment with PC-SPES. This suggests that the components of this herbal mixture, either independently or in combination, acted in colon cancer, resulting in a drastic effect on tumor initiation and tumor progression.




This article has been cited by other articles:


Home page
JPEN J Parenter Enteral NutrHome page
S. Bengmark
Curcumin, An Atoxic Antioxidant and Natural NF{kappa}B, Cyclooxygenase-2, Lipooxygenase, and Inducible Nitric Oxide Synthase Inhibitor: A Shield Against Acute and Chronic Diseases
JPEN J Parenter Enteral Nutr, January 1, 2006; 30(1): 45 - 51.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N.-M. Tsai, S.-Z. Lin, C.-C. Lee, S.-P. Chen, H.-C. Su, W.-L. Chang, and H.-J. Harn
The Antitumor Effects of Angelica sinensis on Malignant Brain Tumors In vitro and In vivo
Clin. Cancer Res., May 1, 2005; 11(9): 3475 - 3484.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. Ikezoe, Y. Yang, D. Heber, H. Taguchi, and H. P. Koeffler
PC-SPES: A Potent Inhibitor of Nuclear Factor-{kappa}B Rescues Mice from Lipopolysaccharide-Induced Septic Shock
Mol. Pharmacol., December 1, 2003; 64(6): 1521 - 1529.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.